Retatrutide is an investigational peptide that Eli Lilly developed under the code LY3437943
doi: 10.14283/jpad.2021.14 17 TramutolaAArenaACiniCButterfieldDABaroneE
That perspective is especially understandable considering that more than half of US adults could be eligible for GLP-1 use either for diabetes, obesity, or heart conditions - the overall population who may want/need access to these drugs is large enough to be cause for concern for any payer - even those as large and well-funded as the US government
Be prepared to discuss this with your doctor so you know what to expect
However, your provider may recommend lifestyle changes to help reduce your risk of developing diverticulitis
Wegovy pen (semaglutide) is an FDA-approved once-weekly subcutaneous injection for chronic weight management in patients with obesity (body mass index of 30 or more) and overweight (body mass index of 27 or more) with a weight-related condition such as cardiovascular disease, high blood pressure, or type 2 diabetes